AVTX
What one share of Avalo Therapeutics holds
Pharmaceutical Preparations
We are a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Our lead product candidate, abdakibart (AVTX-009), an anti-IL-1β monoclonal antibody (“mAb”) is in a Phase 2 clinical trial for hidradenitis suppurativa (“HS”).
Avalo Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$4.18 |
|---|---|
| Cash and investments | $1.61 |
| Book value | $8.48 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | — | −$1,063 | $2.42 | −$684.81 | — | −$277.78 |
| 2023 | — | −$113.58 | $0.57 | −$111.04 | — | — |
| 2024 | $0.06 | −$20.91 | $0.00 | −$6.54 | — | $12.70 |
| 2025 | $0.00 | −$5.84 | — | −$3.84 | — | $4.49 |